{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:23:21Z","timestamp":1778059401519,"version":"3.51.4"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Yueyang Central Hospital","award":["YYSZXYN2023019"],"award-info":[{"award-number":["YYSZXYN2023019"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Methimazole and propylthiouracil are the most common antithyroid drugs. We assessed the safety signals associated with methimazole and propylthiouracil by data mining the FDA pharmacovigilance database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were retrieved from the FAERS database from the 1st quarter of 2004 through the 4th quarter of 2023. A disproportionate analysis of reporting advantage ratios was used to assess potential associations between adverse events and methimazole\/propylthiouracil.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 17,379,609 reports were extracted, of which 5,317 cases of methimazole and 1,761 cases of propylthiouracil were classified as primary suspect reports. After combining the same primary ID, 1586 patients with methimazole and 446 patients with propylthiouracil were retained. We observed 8 categories of SOCs with a reported number\u2009\u2265\u200930 for methimazole and 12 categories of SOCs with a reported number\u2009\u2265\u200910 for propylthiouracil. The median time to adverse events in patients with methimazole was 31 days, with an interquartile range of 31\u201374 days. The median time to adverse events in patients with propylthiouracil was 90 days, with an interquartile range was 20\u2013388.5 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study provided a more in-depth and extensive understanding of adverse events that may be associated with methimazole and propylthiouracil, which will help to reduce the risk of adverse events in the clinical treatment of methimazole and propylthiouracil.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0328889","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T17:29:12Z","timestamp":1755192552000},"page":"e0328889","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil"],"prefix":"10.1371","volume":"20","author":[{"given":"Yun","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1132-9600","authenticated-orcid":true,"given":"Qin","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"5","key":"pone.0328889.ref001","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2018.18","article-title":"Global epidemiology of hyperthyroidism and hypothyroidism","volume":"14","author":"PN Taylor","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"pone.0328889.ref002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.beem.2009.08.013","article-title":"Iodine intake as a determinant of thyroid disorders in populations","volume":"24","author":"P Laurberg","year":"2010","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"pone.0328889.ref003","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1210\/jc.2013-2409","article-title":"The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis","volume":"99","author":"A Garmendia Madariaga","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0328889.ref004","doi-asserted-by":"crossref","first-page":"651534","DOI":"10.3389\/fendo.2021.651534","article-title":"Hyperthyroidism Prevalence in China After Universal Salt Iodization","volume":"12","author":"C Wang","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"pone.0328889.ref005","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/105072501300176417","article-title":"Environmental iodine intake affects the type of nonmalignant thyroid disease","volume":"11","author":"P Laurberg","year":"2001","journal-title":"Thyroid"},{"issue":"5","key":"pone.0328889.ref006","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1530\/EJE-10-1155","article-title":"Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study","volume":"164","author":"A Carl\u00e9","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"10428","key":"pone.0328889.ref007","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0140-6736(23)02016-0","article-title":"Hyperthyroidism","volume":"403","author":"L Chaker","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"pone.0328889.ref008","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1021\/ar4001229","article-title":"Antithyroid drugs and their analogues: synthesis, structure, and mechanism of action","volume":"46","author":"D Manna","year":"2013","journal-title":"Acc Chem Res"},{"issue":"8","key":"pone.0328889.ref009","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1726-4901(09)70402-2","article-title":"Antithyroid drug-induced agranulocytosis","volume":"72","author":"M-T Sun","year":"2009","journal-title":"J Chin Med Assoc"},{"issue":"10","key":"pone.0328889.ref010","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1089\/thy.2019.0045","article-title":"Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves\u2019 Disease in Japan","volume":"29","author":"N Suzuki","year":"2019","journal-title":"Thyroid"},{"issue":"8","key":"pone.0328889.ref011","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrneph.2012.108","article-title":"Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis","volume":"8","author":"M Chen","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"pone.0328889.ref012","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40620-014-0063-2","article-title":"Clinico-pathological features and outcomes of patients with propylthiouracil-associated ANCA vasculitis with renal involvement","volume":"27","author":"Y Chen","year":"2014","journal-title":"J Nephrol"},{"issue":"22","key":"pone.0328889.ref013","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.2169\/internalmedicine.51.8486","article-title":"ANCA-associated vasculitis with central retinal artery occlusion developing during treatment with methimazole","volume":"51","author":"T Yasude","year":"2012","journal-title":"Intern Med"},{"issue":"11","key":"pone.0328889.ref014","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1089\/thy.2019.0589","article-title":"Association Between Thionamides and Acute Pancreatitis: A Case-Control Study","volume":"30","author":"J-Y Guo","year":"2020","journal-title":"Thyroid"},{"issue":"12","key":"pone.0328889.ref015","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa544","article-title":"Methimazole Treatment and Risk of Acute Pancreatitis: A Population-based Cohort Study","volume":"105","author":"A Pecere","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0328889.ref016","doi-asserted-by":"crossref","first-page":"1333662","DOI":"10.3389\/fphar.2024.1333662","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"B Zhao","year":"2024","journal-title":"Front Pharmacol"},{"issue":"11","key":"pone.0328889.ref017","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States Food and Drug Administration Adverse Event Reporting System events for vinca alkaloids: comparing vinorelbine and Vincristine","volume":"23","author":"C Zhong","year":"2024","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"pone.0328889.ref018","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Y Wang","year":"2024","journal-title":"Andrology"},{"issue":"6","key":"pone.0328889.ref019","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"B Zhao","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"pone.0328889.ref020","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"H Yang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"pone.0328889.ref021","doi-asserted-by":"crossref","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"C Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"2","key":"pone.0328889.ref022","article-title":"Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"RJ Yu","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"pone.0328889.ref023","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2217\/cer-2017-0006","article-title":"Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study","volume":"6","author":"SP Marimuthu","year":"2017","journal-title":"J Comp Eff Res"},{"issue":"9","key":"pone.0328889.ref024","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1089\/thy.2019.0180","article-title":"Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves\u2019 Disease: Results of a Randomized Clinical Trial","volume":"29","author":"F Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"5","key":"pone.0328889.ref025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1089\/thy.2018.0397","article-title":"Treatment of Toxic Multinodular Goiter: Comparison of Radioiodine and Long-Term Methimazole Treatment","volume":"29","author":"F Azizi","year":"2019","journal-title":"Thyroid"},{"issue":"8","key":"pone.0328889.ref026","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1089\/thy.2016.0222","article-title":"Antithyroid Drugs-The Most Common Treatment for Graves\u2019 Disease in the United States: A Nationwide Population-Based Study","volume":"26","author":"JP Brito","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"pone.0328889.ref027","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000490384","article-title":"2018 European Thyroid Association Guideline for the Management of Graves\u2019 Hyperthyroidism","volume":"7","author":"GJ Kahaly","year":"2018","journal-title":"Eur Thyroid J"},{"issue":"3","key":"pone.0328889.ref028","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1089\/thy.2018.0315","article-title":"Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves\u2019 Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey","volume":"29","author":"O T\u00f6rring","year":"2019","journal-title":"Thyroid"},{"issue":"15","key":"pone.0328889.ref029","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jama.2023.19052","article-title":"Hyperthyroidism: A Review","volume":"330","author":"SY Lee","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"pone.0328889.ref030","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s40618-020-01479-z","article-title":"Change in newly diagnosed Graves\u2019 disease phenotype between the twentieth and the twenty-first centuries: meta-analysis and meta-regression","volume":"44","author":"S Ippolito","year":"2021","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"pone.0328889.ref031","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/thy.2006.16.573","article-title":"Prevalence of postpartum thyroid dysfunction: a quantitative review","volume":"16","author":"WK Nicholson","year":"2006","journal-title":"Thyroid"},{"issue":"2","key":"pone.0328889.ref032","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP-2019-0221","article-title":"Side effects of ptu and mmi in the treatment of hyperthyroidism: a systematic review and meta-analysis","volume":"26","author":"W Yu","year":"2020","journal-title":"Endocr Pract"},{"issue":"7","key":"pone.0328889.ref033","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1089\/thy.2023.0030","article-title":"A Disproportionality Analysis of the Adverse Effect Profiles of Methimazole and Propylthiouracil in Patients with Hyperthyroidism Using the Japanese Adverse Drug Event Report Database","volume":"33","author":"M Arai","year":"2023","journal-title":"Thyroid"},{"issue":"7","key":"pone.0328889.ref034","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1507\/endocrj.EJ24-0135","article-title":"Dose-dependent incidence of agranulocytosis in patients treated with methimazole and propylthiouracil","volume":"71","author":"J Yoshimura Noh","year":"2024","journal-title":"Endocr J"},{"issue":"9","key":"pone.0328889.ref035","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/bcp.13989","article-title":"Associations of HLA genotypes with antithyroid drug-induced agranulocytosis: A systematic review and meta-analysis of pharmacogenomics studies,","volume":"85","author":"WT Chen","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"pone.0328889.ref036","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0031","article-title":"Long-term methimazole therapy in Graves\u2019 hyperthyroidism and adverse reactions: a Danish multicenter study","volume":"11","author":"J Karmisholt","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"5","key":"pone.0328889.ref037","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/jama.1980.03300310046021","article-title":"Propylthiouracil-induced cutaneous vasculitis. Case presentation and review of the literature","volume":"243","author":"DB Vasily","year":"1980","journal-title":"JAMA"},{"issue":"7","key":"pone.0328889.ref038","first-page":"282","article-title":"Propylthiouracil-induced cutaneous vasculitis","volume":"35","author":"S Yarman","year":"1997","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"pone.0328889.ref039","article-title":"Propylthiouracil-Induced Skin Vasculitis","volume":"14","author":"MS Almeida","year":"2022","journal-title":"Cureus"},{"issue":"30","key":"pone.0328889.ref040","article-title":"The efficiency and safety of methimazole and propylthiouracil in hyperthyroidism: A meta-analysis of randomized controlled trials","volume":"100","author":"S Tan","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"pone.0328889.ref041","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1089\/thy.2014.0603","article-title":"Antineutrophil Cytoplasmic Antibody-Positive Small-Vessel Vasculitis Associated with Antithyroid Drug Therapy: How Significant Is the Clinical Problem?","volume":"25","author":"A-S Balavoine","year":"2015","journal-title":"Thyroid"},{"issue":"8","key":"pone.0328889.ref042","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1210\/jc.2008-2700","article-title":"Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs","volume":"94","author":"JY Noh","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"pone.0328889.ref043","first-page":"5748938","article-title":"Methimazole-Induced Pleural Effusion in the Setting of Graves\u2019 Disease","volume":"2019","author":"LY Khine","year":"2019","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"pone.0328889.ref044","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40360-017-0121-1","article-title":"Methimazole associated eosinophilic pleural effusion: a case report","volume":"18","author":"P Gaspar-da-Costa","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"pone.0328889.ref045","article-title":"A 27-year-old woman presenting with refractory hypoxaemic respiratory failure, haemoptysis and thyrotoxicosis: a rare manifestation of propylthiouracil therapy","volume":"2014","author":"EO Ortiz-Diaz","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"4","key":"pone.0328889.ref046","doi-asserted-by":"crossref","DOI":"10.5812\/ircmj.23320","article-title":"Propylthiouracil-Induced Vasculitis With Alveolar Hemorrhage Confirmed by Clinical, Laboratory, Computed Tomography, and Bronchoscopy Findings: A Case Report and Literature Review","volume":"18","author":"B Chen","year":"2016","journal-title":"Iran Red Crescent Med J"},{"key":"pone.0328889.ref047","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-208289","article-title":"Diffuse alveolar haemorrhage secondary to propylthiouracil-induced vasculitis","volume":"2015","author":"C Ferreira","year":"2015","journal-title":"BMJ Case Rep"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328889","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T17:29:19Z","timestamp":1755192559000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328889"}},"subtitle":[],"editor":[{"given":"Vijayalakshmi","family":"Kakulapati","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328889","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}